Jaguar Health (NASDAQ: JAGX) posted a second-quarter loss per share of $15.68, exceeding analyst expectations by $36.47 compared with the consensus estimate of a $52.15 loss.
Revenue for the period totaled $1.23 million, missing the $4.24 million forecast by 71%. The company has seen one positive earnings-per-share revision over the past 90 days, with no negative adjustments recorded.
Shares of Jaguar Health closed at $0.92, down 68.24% over the past three months and 98.59% over the past year. The stock’s performance has been flagged by InvestingPro as having "fair performance" based on its financial health score.
